Global Meningococcal Vaccines Market 2014-2018

About Meningococcal Vaccines
Meningitis is characterized by the inflammation of the protective lining (meninges) present around the brain and the spinal cord. On the basis of its underlying cause, meningitis can be classified into infectious and non-infectious meningitis. In terms of the type of organism, infectious meningitis can be sub-divided into bacterial meningitis, viral meningitis, fungal meningitis, and parasitic meningitis. Bacterial meningitis is the life-threatening form of infectious meningitis, which can occur due to infection by different bacterial species such as Hemophilus influenza, Listeria monocytogenes, Neisseria meningitides, and Streptococcus pneumonia. Bacterial infection can spread to the blood stream, leading to septicemia. An infection by Neisseria meningitides can lead to meningococcal disease, which is associated with the simultaneous occurrence of meningitis and septicemia. Meningococcal disease can occur at any age; however, it is more prevalent in infants and adolescents. Meningococcal disease involves a sudden onset of symptoms which can lead to death within hours, if left untreated. Disease survivors can recover fully or may suffer from long-term after effects such as neurological defects. Meningococcal disease is generally treated with antibiotics. Preventive measures involve the administration of meningococcal vaccines.
TechNavio's analysts forecast the Global Meningococcal Vaccines market to grow at a CAGR of 15.00 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Meningococcal Vaccines market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the administration of various vaccines to actively immunize meningococcal disease caused by different serogroups of Neisseria meningitides.
TechNavio's report, the Global Meningococcal Vaccines Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Meningococcal Vaccines market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions
‧ Americas
‧ APAC
‧ EMEA
Key Vendors
‧ GlaxoSmithKline
‧ Novartis
‧ Sanofi Pasteur
Other Prominent Vendors
‧ Beijing Minhai Biotechnology
‧ Bio Med
‧ Hualan Biological Engineering
‧ Imunoloski Zavod
‧ JN International Medical
‧ Nuron Biotech
‧ Pfizer
‧ Serum Institute of India
‧ Vacunas Finlay
Market Driver
‧ Designated as Traveler's Vaccine
‧ For a full, detailed list, view our report
Market Challenge
‧ Require Cold Storage
‧ For a full, detailed list, view our report
Market Trend
‧ Combination Vaccines
‧ For a full, detailed list, view our report
Key Questions Answered in this Report
‧ What will the market size be in 2018 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
05.1 Market Overview
05.2 Market Size and Forecast
05.3 Five Forces Analysis
06. Market Segmentation by Composition
06.1 Mono Vaccine
06.1.1 Polysaccharide Vaccines
06.1.2 Conjugate Vaccines
06.2 Combination Vaccines
07. Geographical Segmentation
08. Key Leading Countries
08.1 US
08.2 Brazil
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
16.1 Competitive Scenario
16.1.1 Key News
16.2 Market Share Analysis 2013
16.2.1 GlaxoSmithKline
16.2.2 Sanofi Pasteur
16.2.3 Novartis
16.3 Other Prominent and Future Vendors
17. Late-stage Pipeline Candidates
17.1 Key Information for Late-stage Pipeline Candidates
17.1.1 Bexsero
17.1.2 rLP2086
17.1.3 MCV-ACYW135 Vaccine
18. Key Vendor Analysis
18.1 GlaxoSmithKline
18.1.1 Key Facts
18.1.2 Business Overview
18.1.3 Business Segmentation
18.1.4 Business Segmentation by Revenue 2012 and 2013
18.1.5 Sales by Geography
18.1.6 Pipeline Products
18.1.7 Business Strategy
18.1.8 Key Information
18.1.9 SWOT Analysis
18.2 Novartis
18.2.1 Key Facts
18.2.2 Business Overview
18.2.3 Business Segmentation by Revenue 2013
18.2.4 Business Segmentation by Revenue 2012 and 2013
18.2.5 Sales by Geography
18.2.6 Business Strategy
18.2.7 Key Developments
18.2.8 SWOT Analysis
18.3 Sanofi Pasteur
18.3.1 Key Facts
18.3.2 Business Overview
18.3.3 Business Strategy
18.3.4 Recent Developments
18.3.5 SWOT Analysis
19. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Meningococcal Vaccines Market 2013-2018 (US$ billion)
Exhibit 3: Global Meningococcal Vaccines Market Segmentation by Composition
Exhibit 4: Global Meningococcal Vaccines Market by Geographical Segmentation 2013
Exhibit 5: Global Meningococcal Vaccines Market Share by Leading Countries 2013
Exhibit 6: GlaxoSmithkline's Vaccines: Percentage Share in GlaxoSmithKline Turnover 2013
Exhibit 7: Sanofi's Vaccines: Percentage Share in Sanofi Net Sales 2013
Exhibit 8: Novartis' Vaccines and Diagnostics: Percentage Share in Novartis Net Sales 2013
Exhibit 9: GlaxoSmithKline plc: Business Segmentation 2013
Exhibit 10: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 11: GlaxoSmithKline plc: Sales by Geography 2013
Exhibit 12: GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 13: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 14: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 15: Novartis AG: Sales by Geography 2013